#United States #Las Vegas #Financials #PurMinds #PCAOB Audit

PurMinds Enterprises: Advancing Its Strategic Goals

On June 12, 2026, PurMinds Enterprises, Inc., formerly known as Pacific Software, Inc., submitted its fiscal second quarter financials for the period ended March 31, 2026, to OTC Markets. This represents a critical step for the clinical-stage biotech company focused on precision medicine and neuroscience. The company’s management has laid out a comprehensive operational plan aimed at enhancing its financial position and advancing its clinical pipeline. This update is particularly noteworthy as the company has positioned itself for growth amidst a transformative phase in the public market.

Financial Overview

The financial report disclosed a rigorous effort by PurMinds to streamline operations and fortify its capital structure. Although the revenue and gross profit remained at zero, unchanged from the previous fiscal year, significant measures were taken to optimize the balance sheet. The company canceled 1.5 million legacy common shares and retired all outstanding Series A preferred stock, creating a leaner financial model conducive to growth. Furthermore, the cancellation of specific liabilities, including $300,000 in legacy promissory notes, underscores the company’s commitment to financial integrity.

In terms of new capital raised, PurMinds has demonstrated robust financial inflows, surpassing $2.25 million since its reverse takeover (RTO). This achievement includes significant investment contributions through Regulations S and D, indicating strong investor confidence in the company's future. Additionally, $350,400 has been allocated toward research and development initiatives aimed at advancing the clinical pipeline and diagnostic applications, which are set to enhance the company's offerings in neuromedicine.

PCAOB Audit Initiatives

A pivotal aspect of PurMinds’ strategy involves the launch of a PCAOB (Public Company Accounting Oversight Board) audit, a crucial step necessary for the company's application to up-list to either the OTCQB or OTCQX market tiers. Spearheaded by the recently appointed CFO, Angelo Pizzuto, this audit not only aims to bolster transparency but also fortify the confidence of institutional investors.

Preliminary work for the PCAOB audit began on May 6, 2026, with the hiring of an independent third-party firm. This audit preparation firm is instrumental in optimizing financial records and ensuring readiness for the upcoming PCAOB audit process. The partnership aims for a smooth transition to the audit phase, thus designed to facilitate effective communication with the principal PCAOB audit firm.

Future Planning and Regulatory Compliance

PurMinds is simultaneously working on necessary corporate name and ticker symbol changes. These adjustments are part of the company’s broader strategy to ensure it remains compliant with regulatory frameworks while enhancing its public identity. Once the PCAOB audit is finalized, PurMinds will collaborate with an institutional market maker to submit a Rule 15c2-11 application, liberating it from previous shell constraints and re-establishing a transparent public presence.

Executive Insights

Management emphasizes a commitment to executing its strategic plans effectively as the company transitions into high-growth phases. Janet Qi, CEO, and Angelo Pizzuto, CFO, jointly stated, "Moving deeper into fiscal 2026, management is strictly execution-focused... Cleansing our legacy obligations, bringing in strong private investment capital, executing this PCAOB audit, and driving our strategic commercialization initiatives are the foundational steps required to scale our corporate runway and achieve our targeted clinical milestones over the next 24 months."

About PurMinds Enterprises, Inc.

PurMinds is focused on creating an integrated ecosystem for precision medicine, specifically targeting neurological disorders through advanced therapy development and decentralized diagnostic solutions. The company has an exclusive partnership with SpectroChip Global Inc., which has engineered a groundbreaking photonic chip diagnostic system. This innovative system represents a paradigm shift in delivering rapid diagnostics directly to patients, enhancing healthcare accessibility and efficiency.

For more detailed information about PurMinds Enterprises, please visit www.PurMinds.com.

Forward-Looking Statements

This article contains forward-looking statements regarding PurMinds’ audit timelines, potential capital increases, and future business strategies. While these insights are based on current evaluations, they are subject to risks and uncertainties that may lead to variations from the anticipated results. PurMinds does not intend to update these statements publicly, should changes occur.